WO2022175848 - METHODS OF TREATING HEART FAILURE WITH VIBEGRON
National phase entry:
Publication Number
WO/2022/175848
Publication Date
25.08.2022
International Application No.
PCT/IB2022/051393
International Filing Date
16.02.2022
Title **
[English]
METHODS OF TREATING HEART FAILURE WITH VIBEGRON
[French]
MÉTHODES DE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE AU MOYEN DE VIBEGRON
Applicants **
UROVANT SCIENCES GMBH
Gotthardstrasse 3
6300 Zug, CH
Inventors
ZHOU, Jihao
c/o Urovant Sciences, Inc.
5281 California Avenue, Suite 100
Irvine, California 92617, US
Priority Data
63/150,044
16.02.2021
US
63/294,891
30.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3382 | |
| EPO | Filing, Examination | 43287 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 15710 |
Total: 63581 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides methods of treating or preventing heart failure and/or one or more symptoms thereof, the methods comprising administering to a subject in need thereof a therapeutically effective amount of vibegron.[French]
La présente invention concerne des méthodes de traitement ou de prévention de l'insuffisance cardiaque et/ou d'un ou plusieurs symptômes de celle-ci, lesdites méthodes comprenant l'administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace de vibegron.